Combined treatment with Z-ligustilide significantly restored the anticancer activity of tamoxifen in estrogen receptor α negative (ERα−) breast cancer cells by activating the protein expression and transcriptional activity of ERα35. This evidence concerns the gene ESR1 and breast cancer.